10x Genomics, Inc. (TXG)
- GuruFocus.com
Vanguard Group's Strategic Acquisition in 10x Genomics Inc
On September 30, 2024, Vanguard Group Inc, a prominent investment firm, expanded its portfolio by acquiring an additional 783,673 shares of 10x Genomics Inc (NASDAQ:TXG), a leader in the life science technology sector. This transaction, executed at a price of $22.58 per share, increased Vanguard's total holdings in the company to 10,972,930 shares, marking a significant endorsement of TXG's potential in the healthcare technology market. Founded in 1975 by John C. Bogle, Vanguard Group Inc has revolutionized the investment world with its low-cost, client-focused fund offerings.
- PR Newswire
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting
At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, shared new details about its upcoming product roadmap and its ongoing strategy to democratize access to single cell analysis.
- Simply Wall St.
10x Genomics (NASDAQ:TXG) investors are sitting on a loss of 85% if they invested three years ago
10x Genomics, Inc. ( NASDAQ:TXG ) shareholders should be happy to see the share price up 15% in the last quarter. But...
